a unified approach to higher risk mds: standard and emerging therapies
Published 8 years ago • 189 plays • Length 22:08Download video MP4
Download video MP3
Similar videos
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
24:04
my approach to mds management
-
22:13
how to approach hma failure?
-
18:42
case discussion: high-risk myelodysplastic syndromes
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
19:12
an approach to diagnosis and staging of mds: from morphology to genetics
-
2:50
how is higher-risk mds treated?
-
22:41
new opportunities in experimental therapeutics in mds
-
0:55
the unmet needs in low-risk mds
-
1:51
factors driving the transformation of chip to mds
-
6:48
classification and characteristics of mds
-
17:29
somatic mutations of rna splicing machinery in mds
-
23:21
key insights in mpn & mds: from the us focus on mpn & mds 2017
-
1:27:40
what is mds? how do we determine prognosis?
-
23:37
optimal use of lenalidomide as therapy for mds
-
2:28
immunosuppressive therapy in myelodysplastic syndrome
-
1:17
how is higher-risk mds-related anemia treated?
-
1:11
personalized risk assessment for transplantation in primary immunodeficiency disorders